Agilon Health (AGL)
(Delayed Data from NYSE)
$6.75 USD
-0.01 (-0.15%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $6.73 -0.02 (-0.30%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Agilon Health (AGL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.93 | $18.00 | $5.00 | 17.31% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Agilon Health comes to $7.93. The forecasts range from a low of $5.00 to a high of $18.00. The average price target represents an increase of 17.31% from the last closing price of $6.76.
Analyst Price Targets (17)
Broker Rating
Agilon Health currently has an average brokerage recommendation (ABR) of 2.55 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 2.48 a month ago based on 21 recommendations.
Of the 20 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 25% and 5% of all recommendations. A month ago, Strong Buy made up 28.57%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 13 | 13 | 13 | 13 | 12 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.55 | 2.55 | 2.48 | 2.48 | 2.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
7/9/2024 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Hold |
5/8/2024 | Wells Fargo Securities | Stephen Baxter | Strong Buy | Strong Buy |
5/8/2024 | SVB Securities | Whit Mayo | Hold | Hold |
5/7/2024 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
4/22/2024 | Not Identified | Not Identified | Not Available | Hold |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Sell |
2/29/2024 | The Benchmark Company | William Sutherland | Strong Buy | Strong Buy |
2/28/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1/8/2024 | Not Identified | Not Identified | Not Available | Hold |
12/11/2023 | Goldman Sachs | Jamie Perse | Strong Buy | Hold |
12/6/2023 | JMP Securities | Constantine Kyriakos Davides | Not Available | Strong Buy |
11/1/2023 | BTIG | David M Larsen | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.55 |
ABR (Last week) | 2.55 |
# of Recs in ABR | 20 |
Average Target Price | $7.93 |
LT Growth Rate | 35.20% |
Industry | Medical Services |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.07 |